Literature DB >> 17963006

Failure to recognize multiple endocrine neoplasia 2B: more common than we think?

Curtis J Wray1, Thereasa A Rich, Steven G Waguespack, Jeffrey E Lee, Nancy D Perrier, Douglas B Evans.   

Abstract

BACKGROUND: Multiple endocrine neoplasia 2B (MEN2B) has a classic childhood phenotypic presentation characterized by mucosal neuromas and marfanoid habitus. However, the diagnosis of MEN2B is often delayed beyond childhood, at which time medullary thyroid carcinoma (MTC) may be regionally advanced or metastatic. We examined the extent of this delay and its impact on the treatment of MTC.
METHODS: Patients in the MEN database were retrospectively analyzed to determine the age at first presentation for a MEN2B-related complaint and the subsequent time to correct diagnosis. Operative and pathology reports were reviewed to determine the extent of thyroidectomy and cervical lymphadenectomy during the initial and subsequent neck operations.
RESULTS: We identified 22 patients with MEN2B, 20 were de novo cases and a M918T RET gene mutation was confirmed in 18 of the 22 patients. Median age at diagnosis of MTC was 13 years (range 6-25 years). The median delay in diagnosis was 26 months (range 0-18 years). Persistent local-regional MTC was present following the initial cervical operation in 12 of 22 patients (55%); including 4 of 13 with MEN2B diagnosed prior to initial surgery and 8 of 9 with MEN2B diagnosed after initial surgery.
CONCLUSIONS: Most patients displayed phenotypic characteristics of MEN2B long before the correct diagnosis was made. Half of the patients failed to undergo complete resection of MTC at their initial thyroid surgery. Early recognition of the MEN2B phenotype with a thoughtful approach to preoperative staging and surgery will maximize control of MTC and minimize the need for reoperation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963006     DOI: 10.1245/s10434-007-9665-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.

Authors:  Sina Jasim; Anita K Ying; Steven G Waguespack; Thereasa A Rich; Elizabeth G Grubbs; Camilo Jimenez; Mimi I Hu; Gilbert Cote; Mouhammed Amir Habra
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 3.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

4.  A family presenting with multiple endocrine neoplasia type 2B: A case report.

Authors:  Mahnaz Majidi; Vahid Haghpanah; Mahdi Hedayati; Patricia Khashayar; Mohammad Reza Mohajeri-Tehrani; Bagher Larijani
Journal:  J Med Case Rep       Date:  2011-12-20

Review 5.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

Review 6.  Understanding what determines the frequency and pattern of human germline mutations.

Authors:  Norman Arnheim; Peter Calabrese
Journal:  Nat Rev Genet       Date:  2009-07       Impact factor: 53.242

7.  Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.

Authors:  Frederic Castinetti; Steven G Waguespack; Andreas Machens; Shinya Uchino; Kornelia Hasse-Lazar; Gabriella Sanso; Tobias Else; Sarka Dvorakova; Xiao Ping Qi; Rossella Elisei; Ana Luisa Maia; John Glod; Delmar Muniz Lourenço; Nuria Valdes; Jes Mathiesen; Nelson Wohllk; Tushar R Bandgar; Delphine Drui; Marta Korbonits; Maralyn R Druce; Caroline Brain; Tom Kurzawinski; Atila Patocs; Maria Joao Bugalho; Andre Lacroix; Philippe Caron; Patricia Fainstein-Day; Francoise Borson Chazot; Marc Klein; Thera P Links; Claudio Letizia; Laura Fugazzola; Olivier Chabre; Letizia Canu; Regis Cohen; Antoine Tabarin; Anita Spehar Uroic; Dominique Maiter; Sandrine Laboureau; Caterina Mian; Mariola Peczkowska; Frederic Sebag; Thierry Brue; Delphine Mirebeau-Prunier; Laurence Leclerc; Birke Bausch; Amandine Berdelou; Akihiro Sukurai; Petr Vlcek; Jolanta Krajewska; Marta Barontini; Carla Vaz Ferreira Vargas; Laura Valerio; Lucieli Ceolin; Srivandana Akshintala; Ana Hoff; Christian Godballe; Barbara Jarzab; Camilo Jimenez; Charis Eng; Tsuneo Imai; Martin Schlumberger; Elizabeth Grubbs; Henning Dralle; Hartmut P Neumann; Eric Baudin
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-16       Impact factor: 32.069

Review 8.  Multiple endocrine neoplasias type 2B and RET proto-oncogene.

Authors:  Giuseppe Martucciello; Margherita Lerone; Lara Bricco; Gian Paolo Tonini; Laura Lombardi; Carmine G Del Rossi; Sergio Bernasconi
Journal:  Ital J Pediatr       Date:  2012-03-19       Impact factor: 2.638

9.  Multiple endocrine neoplasia-2B presenting with orthodontic relapse.

Authors:  Brent Accurso; Ana Mercado; Carl M Allen
Journal:  Angle Orthod       Date:  2010-05       Impact factor: 2.079

10.  A Case of Multiple Endocrine Neoplasia Type 2B and Gangliomatosis of Gastrointestinal Tract.

Authors:  Banafshe Shahnazari; Aria Aghamaleki; Bagher Larijani; Mohammad Reza Mohajeri Tehrani; Hasan Rafati; Abdolreza Babamahmoodi
Journal:  Case Rep Med       Date:  2012-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.